与联合使用 ACEI+ARB 全剂量滴定相比,使用半剂量 ACEI+ARB 联合滴定可更好地降低蛋白尿。

Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.

机构信息

Nephrology, Nice University Hospital, Nice Sophia-Antipolis University, Nice, France.

出版信息

Nephrol Dial Transplant. 2010 Jul;25(7):2218-24. doi: 10.1093/ndt/gfp776. Epub 2010 Jan 26.

Abstract

BACKGROUND

Residual proteinuria is a strong modifiable risk factor for renal failure progression. We previously showed that the antiproteinuric effect of combined half doses of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) is increased by raising diuretic dosage. Methods. We tested whether uptitration of loop diuretics on top of combined half doses of ACEI and ARB would better decrease proteinuria than uptitration to combined full doses of ACEI and ARB in a randomized, crossover, three periods of 6-week controlled study. Eighteen patients with stable proteinuria over 1 g/day with combined ramipril at 5 mg/day and valsartan at 80 mg/day in addition to conventional antihypertensive treatments were randomized to receive combined ramipril at 5 mg/day and valsartan at 80 mg/day, or combined ramipril at 10 mg/day and valsartan at 160 mg/day, or combined ramipril at 5 mg/day, valsartan at 80 mg/day and increased furosemide dosage in random order. The primary end point was the mean urinary protein/creatinine ratio in two 24-hour urine collections at the end of the three treatment periods. Secondary end points included mean 24-hour proteinuria, home systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP) and estimated glomerular filtration rate (eGFR) levels.

RESULTS

The geometric mean urinary protein/creatinine ratio was lower with combined ramipril at 5 mg/day, valsartan at 80 mg/day and increased furosemide dosage compared to combined ramipril at 5 mg/day and valsartan at 80 mg/day, but also to combined ramipril at 10 mg/day and valsartan at 160 mg/day. These differences remained significant after adjustment for SBP, DBP or MAP and 24-hour natriuresis but not after adjustment on eGFR. Diuretic dosage uptitration did not increase the number of home systolic blood pressure measurements below 100 mmHg, but led to a statistically significant increase in the number of symptomatic hypotension episodes.

CONCLUSIONS

A cautious uptitration of loop diuretic dosage in addition to combined half doses of ACEI and ARB better decrease proteinuria in patients with CKD and high residual proteinuria than uptitration to full dose of combined ACEI and ARB. This antiproteinuric effect of diuretics was partly explained by an eGFR decrease, suggesting the contribution of haemodynamic modifications, whose safety on the long term still need to be addressed.

摘要

背景

残余蛋白尿是肾功能衰竭进展的一个强烈可改变的危险因素。我们之前曾表明,通过增加利尿剂剂量,联合使用半剂量血管紧张素转换酶抑制剂(ACEI)和血管紧张素受体阻滞剂(ARB)的降蛋白尿作用会增加。方法:我们在一项随机、交叉、三周期 6 周对照研究中测试了在联合使用半剂量 ACEI 和 ARB 的基础上加用袢利尿剂是否比加用 ACEI 和 ARB 的全剂量更能降低蛋白尿。18 例蛋白尿稳定在 1 克/天以上的患者,在常规降压治疗的基础上加用每天 5 毫克雷米普利和 80 毫克缬沙坦,随机分为三组,分别接受联合雷米普利 5 毫克/天、缬沙坦 80 毫克/天,或联合雷米普利 10 毫克/天、缬沙坦 160 毫克/天,或联合雷米普利 5 毫克/天、缬沙坦 80 毫克/天和增加呋塞米剂量。主要终点是三个治疗期结束时两次 24 小时尿液收集的平均尿蛋白/肌酐比值。次要终点包括平均 24 小时蛋白尿、家庭收缩压(SBP)、舒张压(DBP)、平均动脉压(MAP)和估算肾小球滤过率(eGFR)水平。

结果

与联合使用雷米普利 5 毫克/天和缬沙坦 80 毫克/天相比,联合使用雷米普利 5 毫克/天、缬沙坦 80 毫克/天和增加呋塞米剂量组的尿蛋白/肌酐比值几何均数较低,但也低于联合使用雷米普利 10 毫克/天和缬沙坦 160 毫克/天组。这些差异在调整 SBP、DBP 或 MAP 和 24 小时钠排泄量后仍然显著,但在调整 eGFR 后则不显著。利尿剂剂量的调整并没有增加家庭收缩压测量值低于 100mmHg 的次数,但导致症状性低血压发作次数的统计学显著增加。

结论

在联合使用半剂量 ACEI 和 ARB 的基础上谨慎增加袢利尿剂剂量,可降低 CKD 伴高残余蛋白尿患者的蛋白尿水平,优于增加 ACEI 和 ARB 的全剂量。利尿剂的这种降蛋白尿作用部分归因于 eGFR 的下降,提示与血液动力学改变有关,其长期安全性仍需解决。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索